 Poly(ADP-ribose) Polymerase Inhibitors
"Poly(ADP-ribose) Polymerase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Chemicals and drugs that inhibit the action of POLY(ADP-RIBOSE)POLYMERASES.
| Descriptor ID |
D000067856
|
| MeSH Number(s) |
D27.505.519.389.739 D27.505.954.248.692
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Poly(ADP-ribose) Polymerase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Poly(ADP-ribose) Polymerase Inhibitors".
This graph shows the total number of publications written about "Poly(ADP-ribose) Polymerase Inhibitors" by people in this website by year, and whether "Poly(ADP-ribose) Polymerase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 | | 2003 | 0 | 1 | 1 | | 2004 | 0 | 2 | 2 | | 2009 | 0 | 1 | 1 | | 2013 | 1 | 0 | 1 | | 2015 | 2 | 0 | 2 | | 2016 | 3 | 1 | 4 | | 2017 | 3 | 0 | 3 | | 2018 | 1 | 2 | 3 | | 2019 | 3 | 0 | 3 | | 2020 | 7 | 1 | 8 | | 2021 | 0 | 1 | 1 | | 2022 | 3 | 3 | 6 | | 2023 | 2 | 4 | 6 | | 2024 | 5 | 5 | 10 | | 2025 | 3 | 3 | 6 | | 2026 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Poly(ADP-ribose) Polymerase Inhibitors" by people in Profiles.
-
Ortega R, Taylor ER, Whitehead SM, Danhorn T, Bitler BG, Arnoult N. PARP1 and PARP2 are dispensable for DNA repair by microhomology-mediated end-joining at double-ended DSBs. Nucleic Acids Res. 2026 Jan 05; 54(1).
-
Willman G, Podder V, Westin SN, Corr BR, Coleman RL, Pothuri B, Moore KN, Slomovitz BM. Homologous recombination deficiency in endometrial cancer: shedding light on recent clinical findings. Int J Gynecol Cancer. 2026 Feb; 36(2):102859.
-
Corr BR, Woodruff ER, Yamamoto TM, Jordan KR, Danhorn T, Bossard C, Nguyen LL, Chuong EB, Wick L, Young A, Kusumoto S, Orsulic S, Barroilhet L, Bitler BG. SM08502-Mediated ß-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression. Cancer Res Commun. 2025 Dec 01; 5(12):2112-2126.
-
Bitler BG, Lang J, Nunez-Avellaneda D, Behbakht K, Davidson NR, Woodruff ER, Villagomez FR. Claudin-4 as a dual regulator of genome stability and immune evasion in high grade serous ovarian cancer. Sci Rep. 2025 Nov 10; 15(1):39257.
-
Graham LS, Yu EY. Early and Precise: Treating HRR Alterations in Hormone-Sensitive Prostate Cancer. Clin Cancer Res. 2025 Oct 01; 31(19):4001-4003.
-
Guo Y, Li Z, Parsels LA, Wang Z, Parsels JD, Dalvi A, The S, Hu N, Valvo VM, Doherty R, Peterson E, Wang X, Venkataraman S, Agnihotri S, Venneti S, Wahl DR, Green MD, Lawrence TS, Koschmann C, Morgan MA, Zhang Q. H3K27M diffuse midline glioma is homologous recombination defective and sensitized to radiotherapy and NK cell-mediated antitumor immunity by PARP inhibition. Neuro Oncol. 2025 Sep 17; 27(8):2129-2146.
-
Corr BR, Haggerty A, Gysler SM, Taylor S, Behbakht K, Alldredge J, Lefkowits C, Brubaker LW, Bouts C, Babayan LM, Martin LP, Costello J, Bitler BG, Hu J, Guntupalli SR. A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer. Gynecol Oncol. 2025 Sep; 200:58-67.
-
Nguyen LL, Watson ZL, Ortega R, Woodruff ER, Jordan KR, Iwanaga R, Yamamoto TM, Bailey CA, To F, Lin S, Villagomez FR, Jeong AD, Guntupalli SR, Behbakht K, Gibaja V, Arnoult N, Chuong EB, Bitler BG. EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell-Dependent Manner. Mol Cancer Res. 2024 12 03; 22(12):1117-1127.
-
Richardson DL, Quintanilha JCF, Danziger N, Li G, Sokol E, Schrock AB, Ebot E, Bhardwaj N, Norris T, Afghahi A, Frachioni A, Washington C, Dockery L, Elvin J, Graf RP, Moore KN. Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice. Clin Cancer Res. 2024 Oct 15; 30(20):4644-4653.
-
Liu J, Berchuck A, Backes FJ, Cohen J, Grisham R, Leath CA, Martin L, Matei D, Miller DS, Robertson S, Barroilhet L, Uppal S, Hendrickson AW, Gershenson DM, Gray HJ, Hakam A, Jain A, Konecny GE, Moroney J, Ratner E, Schorge J, Thaker PH, Werner TL, Zsiros E, Behbakht K, Chen LM, DeRosa M, Eisenhauer EL, Leiserowitz G, Litkouhi B, McHale M, Percac-Lima S, Rodabaugh K, Vargas R, Jones F, Kovach E, Hang L, Ramakrishnan S, Alvarez RD, Armstrong DK. NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024 10; 22(8):512-519.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|